Author:
Dennis Thomas,Gahan Matthew
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. NHS Education for Scotland and Scottish Dental Clinical Effectiveness Programme. Oral Health Management of Patients at Risk of Medication-related Osteonecrosis of the Jaw guidance. 2017. Available at https://www.sdcep.org.uk/wp-content/uploads/2017/04/SDCEP-Oral-Health-Management-of-Patients-at-Risk-of-MRONJ-Guidance-full.pdf (accessed November 2020).
2. Ruggiero S L, Dodson T B, Fantasia J et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw - 2014 update. J Oral Maxillofac Surg 2014; 72: 1938-1956.
3. Saad F, Brown J E, Van Poznak C et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012; 23: 1341-1347.
4. Otto S, Pautke C, Van den Wyngaert T et al. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev 2018; 69: 177-187.
5. Troeltzsch M, Cagna D, Stähler P et al. Clinical features of peri-implant medication-related osteonecrosis of the jaw: Is there an association to peri-implantitis? J Craniomaxillofac Surg 2016; 44: 1945-1951.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献